Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 65Neoplasm Metastasis 11Advanced Breast Cancer 5Neoplasms 4Recurrence 2Multiple Endocrine Neoplasia Type 1 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Hereditary Sensory and Autonomic Neuropathies 2Unilateral Breast Neoplasms 1Neoplasms by Site 1HR-positive, HER2-negative Breast Neoplasms 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1Disease Progression 1Carcinoma, Lobular 1Carcinoma, Ductal, Breast 1Breast Neoplasm Female 1Breast Diseases 1

Interventions

Dexamethasone 28Rituximab 16pomalidomide 13Gemcitabine 12Lenalidomide 11Cisplatin 11Bortezomib 11Paclitaxel 10Cyclophosphamide 8Carboplatin 8carfilzomib 7selinexor 5daratumumab 5Drug Therapy 5Doxorubicin 5Cytarabine 5ibrutinib 4Vincristine 4Temozolomide 4Prednisone 4Docetaxel 4Calcium Dobesilate 4Bevacizumab 4Aspirin 4tisagenlecleucel 3Cetuximab 3Bendamustine Hydrochloride 3venetoclax 2ofatumumab 2galiximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Recurrence × Fulvestrant × Clear all
NCT07062965 2026-05-06

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Pfizer

Phase 3 Recruiting
400 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT00256698 2012-08-01

FACT

AstraZeneca

Phase 3 Completed
514 enrolled 13 charts
Breast

Breast Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡